6 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been notified that Chief Executive Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02 pence each in the Company (“Ordinary Shares”) at a share price of 4.78 pence per share.
Following the purchase, Jeremy Skillington’s beneficial interest in the Company is 718,733 Ordinary Shares, representing 0.14 per cent. of the total issued share capital.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“Following the significant levels of activity and excellent progress that has been made across our growing asset portfolio over recent months, I am pleased to now finally have the opportunity to purchase shares in the Company. Poolbeg is entering a very exciting phase in its development with a number of near-term value inflection points and I am confident in our potential to create future value for the Company and our shareholders through advancing and partnering our pipeline of infectious disease treatments.”
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”).
– Ends –
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+44 (0) 20 7183 1499
